As expected, our results revealed that the knockdown or inhibition of Ezrin effectively restored cell sensitivity to antiestrogens, and subsequently reversed the ERα signaling in endocrine-resistant cancer cells, implying the potential role of Ezrin as a target in overcoming endocrine resistance. Here, ESR1 is linked to cancer.